12 employees
Sentien is a developer of new blood conditioning therapies designed to restore balance to the immune system of critically ill patients.
2008
$12M
from 2 investors over 2 rounds
Sentien Biotechnologies, Inc. raised $12M on April 4, 2017
Investors: Chiesi Ventures and Mass Medical Angels